Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever. M. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022 Dec; 13;12(12):165. doi: 10.1038/s41408-022-00760-z. PMID: 36509740

​

Konrat J, Rösler W, Roiss M, Meier-Abt F, Widmer CC, Balabanov S, Manz MG, Zenz T. BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2. Ann Hematol. 2022 Dec;10;1-4. doi: 10.1007/s00277-022-05026-z. PMID: 36494600

 

Mangolini M, Maiques-Diaz A, Charalampopoulou S, Gerhard-Hartmann E, Bloehdorn J, Moore A, Giachetti G, Lu J,      Roamio Franklin VN, Chilamakuri CSR, Moutsopoulos I, Rosenwald A, Stilgenbauer S, Zenz T, Mohorianu I, D'Santos C,  Deaglio S, Hodson DJ, Martin-Subero JI, Ringshausen I. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape. Nat Commun. 2022 Oct 20;13(1):6220. doi: 10.1038/s41467-022-33739-2. PMID: 36266281 

​

Herbst SA, Vesterlund M, Helmboldt AJ, Jafari R, Siavelis I, Stahl M, Schitter EC, Liebers N, Brinkmann BJ, Czernilofsky F,    Roider T, Bruch PM, Iskar M, Kittai A, Huang Y, Lu J, Richter S, Mermelekas G, Umer HM, Knoll M, Kolb C, Lenze A, Cao X, Österholm C, Wahnschaffe L, Herling C, Scheinost S, Ganzinger M, Mansouri L, Kriegsmann K, Kriegsmann M, Anders S, Zapatka M,  Del Poeta G, Zucchetto A, Bomben R, Gattei V, Dreger P, Woyach J, Herling M, Müller-Tidow C, Rosenquist R, Stilgenbauer S, Zenz T, Huber W, Tausch E, Lehtiö J, Dietrich S. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. Nat Commun. 2022 Oct 20;13(1):6226. doi: 10.1038/s41467-022-33385-8.PMID: 36266272 

​

Batzilla A, Lu J, Kivioja J, Putzker K, Lewis J, Zenz T, Huber W. Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling. PLoS Comput Biol. 2022 Aug 22;18(8):e1010438. doi: 10.1371/journal.pcbi.1010438. eCollection 2022 Aug. PMID: 35994503 

​

Abrisqueta P, Medina-Gil D, Villacampa G, Lu J, Alcoceba M, Carabia J, Boix J, Tazón-Vega B, Iacoboni G, Bobillo S,      Marín-Niebla A, González M, Zenz T, Crespo M, Bosch F. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Adv. 2022 Aug 16:bloodadvances.2022007508. doi: 10.1182/bloodadvances.2022007508. Online ahead of print. PMID: 35973197

​

Bruch PM, Giles HA, Kolb C, Herbst SA, Becirovic T, Roider T, Lu J, Scheinost S, Wagner L, Huellein J, Berest I, Kriegsmann M, Kriegsmann K, Zgorzelski C, Dreger P, Zaugg JB, Müller-Tidow C, Zenz T, Huber W, Dietrich S. Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. Mol Syst Biol. 2022. Aug;18(8):e10855. doi: 10.15252/msb.202110855.PMID: 35959629 

​

Stirm K, Leary P, Bertram K, Núñez NG, Wüst D, Boudesco C, Verhoeyen E, Zenz T, Becher B, Menter T, Tzankov A, Müller A. Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma. Oncoimmunology. 2021 Nov 22;10(1):2003533. doi: 10.1080/2162402X.2021.2003533. PMID: 34858727

​

Bertram K, Leary PJ, Boudesco C, Fullin J, Stirm K, Dalal V, Zenz T, Tzankov A, Müller A. Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. Leukemia. 2021 Nov 18. doi: 10.1038/s41375-021-01470-4. PMID: 34795418

​

Wilke AC, Doebele C, Zindel A, Lee KS, Rieke SA, Ceribelli M, Comoglio F, Phelan JD, Wang JQ, Pikman Y, Jahn D, Häupl B, Schneider C, Scheich S, Tosto FA, Bohnenberger H, Stauder P, Schnuetgen F, Slabicki M, Coulibaly ZA, Wolf S, Bojarczuk K, Chapuy B, Brandts CH, Stroebel P, Lewis CA, Engelke M, Xu X, Kim H, Dang TH, Schmitz R, Hodson DJ, Stegmaier K,      Urlaub H, Serve H, Schmitt CA, Kreuz F, Knittel G, Rabinowitz JD, Reinhardt HC, Vander Heiden MG, Thomas C, Staudt LM, Zenz T, Oellerich T. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.

Blood. 2020 Oct 8:blood.2021012081. doi: 10.1182/blood.2021012081. PMID: 34624079

​

Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl MR, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Beà S, Boldorini R, Broccoli A, Bühler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti SB, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami GG, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia AA, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza FA, Pizzolitto S, Rambaldi A, Sabattini E, Salles GA, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G,    Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, 

de Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F,  Zucca E, Rossi D. Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. Blood. 2021 Oct 15:blood.2021012386. doi: 10.1182/blood.2021012386. PMID: 34653238

​

Lewis R, Maurer HC, Singh N, Gonzalez-Menendez I, Wirth M, Schick M, Zhang L, Isaakidis K, Scherger AK, Schulze V, Lu J, Zenz T, Steiger K, Rad R, Quintanilla-Martinez L, Espeli M, Balabanian K, Keller U, Habringer S. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. Leukemia. 2021 Oct;35(10):2895-2905. doi: 10.1038/s41375-021-01376-1. PMID: 34363012

​

Bühler MM, Lu J, Scheinost S, Nadeu F, Roos-Weil D, Hensel M, Thavayogarajah T, Moch H, Manz MG, Haralambieva E, Marques Maggio E, Beà S, Giné E, Campo E, Bernard OA, Huber W, Zenz T. SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues. Leuk Res. 2021 Aug;107:106608. doi: 10.1016/ j.leukres.2021.106608. PMID: 33979727

​

Lu J, Cannizzaro E, Meier-Abt F, Scheinost S, Bruch P M, Giles H. A. R., Lütge A, Hüllein J, Wagner L,  Giacopelli B, Nadeu F, Delgado J, Campo E., Mangolini M, Ringshausen I, Böttcher M, Mougiakakos D, Jacobs A, Bodenmiller B, Dietrich S,

Oakes C C, Zenz T, Huber W. Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. Nature Cancer. 2021 Aug: doi: 10.1038/s43018-021-00216-6. PMID: 34423310

​

Meier-Abt F, Lu J, Cannizzaro E, Pohly MF, Kummer S, Pfammatter S, Kunz L, Collins BC, Nadeu F, Lee KS, Xue P, Gwerder M, Roiss M, Hüllein J, Scheinost S, Dietrich S, Campo E, Huber W, Aebersold R, Zenz T. The Protein Landscape of Chronic Lymphocytic Leukemia (CLL). Blood. 2021 Jun 29:blood.2020009741. doi: 10.1182/blood.2020009741. 

PMID: 34189564

​

Grever M, Andritsos L, Banerji V, Barrientos JC, Bhat S, Blachly JS, Call T, Cross M, Dearden C, Demeter J, Dietrich S, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Juliusson G, Kraut E, Kreitman RJ, Lauria F, Lozanski G, Parikh SA, Park J, Polliack A, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Zent C, Zenz T, Zinzani PL, Wörmann B. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia 2021 May 4:1-9. doi: 10.1038/s41375-021-01257-7. PMID: 33947938

​

Alankus B, Ecker V, Vahl N, Braun M, Weichert W, Macher-Göppinger S, Gehring T, Neumayer T, Zenz T, Buchner M, Ruland J. Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. J Exp Med. 2021 Feb 1;218(2) doi: 10.1084/jem.20200517. PMID: 33075129

​

Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, Martin S, Lu J, Zenz T, Baumann TS, Jares P, Puente XS, Martin-Subero I, Delgado J, Campo E. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2020 Nov 19: doi: 10.1182/blood.2020008311​. PMID: 33211804

​​

Nadeu F, Mas-de-Les-Valls R, Navarro A, Royo R, Martín S, Villamor N, Suárez-Cisneros H, Mares R, Lu J, Enjuanes A,

Rivas-Delgado A, Aymerich M, Baumann T, Colomer D, Delgado J, Morin RD, Zenz T, Puente XS, Campbell PJ, Beà S, Maura F, Campo E. IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. Nat Commun.2020 Jul 7;11(1):3390. doi:10.1038/s41467-020-17095-7.  

PMID: 32636395

​​​